

## 6 Literaturverzeichnis

1. Abd El-Rehim DM, Pinder SE et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. *Br J Cancer* 91 (8): 1532-1542, 2004.
2. Allred DC, Clark GM et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. *Hum Pathol* 23 (9): 974-979, 1992.
3. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. *FEBS Lett* 410 (1): 83-86, 1997.
4. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. *J Clin Oncol* 19 (18 Suppl): 32S-40S, 2001.
5. Bacus SS, Chin D et al. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. *Am J Pathol* 148 (2): 549-558, 1996.
6. Baselga J, Albanell J et al. Mechanism of action of trastuzumab and scientific update. *Semin Oncol* 28 (5 Suppl 16): 4-11, 2001.
7. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. *Pharmacol Ther* 64 (1): 127-154, 1994.
8. Baselga J, Tripathy D et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. *J Clin Oncol* 14 (3): 737-744, 1996.
9. Battaglia F, Scambia G et al. Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. *Eur J Cancer Clin Oncol* 24 (11): 1685-1690, 1988.
10. Bell R. What can we learn from Herceptin trials in metastatic breast cancer? *Oncology* 63 Suppl 1: 39-46, 2002.
11. Birner P, Oberhuber G et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. *Clin Cancer Res* 7 (6): 1669-1675, 2001.
12. Busmanis I, Feleppa F et al. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. *Pathology* 26 (3): 261-267, 1994.
13. Carlomagno C, Perrone F et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. *J Clin Oncol* 14 (10): 2702-2708, 1996.

14. Carter P, Presta L et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proc Natl Acad Sci U S A* 89 (10): 4285-4289, 1992.
15. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. *Semin Oncol* 15 (2 Suppl 1): 20-25, 1988.
16. Clark GM, Sledge GW, Jr. et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. *J Clin Oncol* 5 (1): 55-61, 1987.
17. Clarke RB, Howell A et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. *Cancer Res* 57 (22): 4987-4991, 1997.
18. Clynes RA, Towers TL et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. *Nat Med* 6 (4): 443-446, 2000.
19. Cobleigh MA, Vogel CL et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 17 (9): 2639-2648, 1999.
20. Cohen S, Taylor JM. Epidermal growth factor: chemical and biological characterization. *Recent Prog Horm Res* 30 (0): 533-550, 1974.
21. Costa S, Stamm H et al. Predictive value of EGF receptor in breast cancer. *Lancet* 2 (8622): 1258, 1988.
22. Cowley SM, Parker MG. A comparison of transcriptional activation by ER  $\alpha$  and ER  $\beta$ . *J Steroid Biochem Mol Biol* 69 (1-6): 165-175, 1999.
23. Dabrosin C, Margetts PJ, Gaudie J. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. *Int J Cancer* 107 (4): 535-540, 2003.
24. DAKO HercepTest: A Manual for Interpretation. DAKO: 2000.
25. Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. *Lab Invest* 55 (5): 588-592, 1986.
26. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. *Endocr Relat Cancer* 8 (3): 191-195, 2001.
27. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. *Oncogene* 2 (3): 273-277, 1988.
28. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. *Oncogene* 2 (4): 387-394, 1988.
29. Drebin JA, Link VC et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. *Cell* 41 (3): 697-706, 1985.

30. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *Lancet* 351 (9114): 1451-1467, 1998.
31. Edgerton SM, Moore D et al. erbB-2 (HER-2) and breast cancer progression. *Appl Immunohistochem Mol Morphol* 11 (3): 214-221, 2003.
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. *Histopathology* 19 (5): 403-410, 1991.
33. Esteva FJ, Hortobagyi GN et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. *Pathol Oncol Res* 7 (3): 171-177, 2001.
34. Fendly BM, Winget M et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. *Cancer Res* 50 (5): 1550-1558, 1990.
35. Ferlay J, Bray F et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5 IARC Press (Version 1.0): 2001.
36. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. *JAMA* 288 (3): 366-368, 2002.
37. Foekens JA, Portengen H et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. *Cancer Res* 49 (24 Pt 1): 7002-7009, 1989.
38. Fuchs IB, Loebbecke M et al. HER2 in brain metastases: issues of concordance, survival, and treatment. *J Clin Oncol* 20 (19): 4130-4133, 2002.
39. Fuchs IB, Siemer I et al. Epidermal growth factor receptor changes during breast cancer metastasis. *Anticancer Res* 26 (6B): 4397-4401, 2006.
40. Fuqua SA. The role of estrogen receptors in breast cancer metastasis. *J Mammary Gland Biol Neoplasia* 6 (4): 407-417, 2001.
41. Fuqua SA, Wiltschke C et al. A hypersensitive estrogen receptor- $\alpha$  mutation in premalignant breast lesions. *Cancer Res* 60 (15): 4026-4029, 2000.
42. Gancberg D, Di Leo A et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. *Ann Oncol* 13 (7): 1036-1043, 2002.
43. Gasparini G, Gullick WJ et al. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma – an immunocytochemical study. *Eur J Cancer* 30A (1): 16-22, 1994.
44. Gilbertson RJ, Perry RH et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. *Cancer Res* 57 (15): 3272-3280, 1997.

45. Goldhirsch A, Glick JH et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. *J Clin Oncol* 19 (18): 3817-3827, 2001.
46. Goldstein NI, Prewett M et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. *Clin Cancer Res* 1 (11): 1311-1318, 1995.
47. Graus-Porta D, Beerli RR et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. *EMBO J* 16 (7): 1647-1655, 1997.
48. Grimaux M, Romain S et al. Prognostic value of epidermal growth factor receptor in node-positive breast cancer. *Breast Cancer Res Treat* 14 (1): 77-90, 1989.
49. Gullick WJ, Marsden JJ et al. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. *Cancer Res* 46 (1): 285-292, 1986.
50. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. *Breast Cancer Res Treat* 52 (1-3): 43-53, 1998.
51. Gustafsson JA. Estrogen receptor  $\beta$  – a new dimension in estrogen mechanism of action. *J Endocrinol* 163 (3): 379-383, 1999.
52. Gusterson B, Cowley G et al. Cellular localisation of human epidermal growth factor receptor. *Cell Biol Int Rep* 8 (8): 649-658, 1984.
53. Gusterson BA, Gelber RD et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. *J Clin Oncol* 10 (7): 1049-1056, 1992.
54. Guy CT, Webster MA et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. *Proc Natl Acad Sci U S A* 89 (22): 10578-10582, 1992.
55. Guy PM, Platko JV et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. *Proc Natl Acad Sci U S A* 91 (17): 8132-8136, 1994.
56. Hancock MC, Langton BC et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. *Cancer Res* 51 (17): 4575-4580, 1991.
57. Harris LN, Liotcheva V et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. *J Clin Oncol* 19 (6): 1698-1706, 2001.
58. Harvey JM, Clark GM et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. *J Clin Oncol* 17 (5): 1474-1481, 1999.
59. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. *J Clin Invest* 74 (2): 647-651, 1984.

60. Heppner GH. Tumor cell societies. *J Natl Cancer Inst* 81 (9): 648-649, 1989.
61. Hudelist G, Singer CF et al. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. *Breast Cancer Res Treat* 80 (3): 353-361, 2003.
62. Hudziak RM, Lewis GD et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. *Mol Cell Biol* 9 (3): 1165-1172, 1989.
63. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. *Proc Natl Acad Sci U S A* 84 (20): 7159-7163, 1987.
64. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim Biophys Acta* 1198 (2-3): 165-184, 1994.
65. Iwao K, Miyoshi Y et al. Quantitative analysis of estrogen receptor- $\beta$  mRNA and its variants in human breast cancers. *Int J Cancer* 88 (5): 733-736, 2000.
66. Izumi Y, Xu L et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. *Nature* 416 (6878): 279-280, 2002.
67. Jacobs TW, Gown AM et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. *J Clin Oncol* 17 (7): 1983-1987, 1999.
68. Jacobs TW, Prioleau JE et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. *J Natl Cancer Inst* 88 (15): 1054-1059, 1996.
69. John HA, Birnstiel ML, Jones KW. RNA-DNA hybrids at the cytological level. *Nature* 223 (206): 582-587, 1969.
70. Kainulainen V, Sundvall M et al. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. *J Biol Chem* 275 (12): 8641-8649, 2000.
71. Karayiannakis AJ, Bastounis EA et al. Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. *Eur J Surg Oncol* 22 (6): 578-582, 1996.
72. Kato S, Masuhiro Y et al. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. *Genes Cells* 5 (8): 593-601, 2000.
73. Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. *Adv Cancer Res* 55: 87-132, 1990.
74. Kew TY, Bell JA et al. c-erbB-4 protein expression in human breast cancer. *Br J Cancer* 82 (6): 1163-1170, 2000.
75. Khan SA, Rogers MA et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. *J Natl Cancer Inst* 90 (1): 37-42, 1998.

76. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). *Curr Opin Oncol* 13 (6): 506-513, 2001.
77. Klapper LN, Kirschbaum MH et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. *Adv Cancer Res* 77: 25-79, 2000.
78. Klijn JG, Berns PM et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. *Endocr Rev* 13 (1): 3-17, 1992.
79. Knight WA, Livingston RB et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. *Cancer Res* 37 (12): 4669-4671, 1977.
80. Knowlden JM, Gee JM et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. *Oncogene* 17 (15): 1949-1957, 1998.
81. Koenders PG, Beex LV et al. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. *Breast Cancer Res Treat* 18 (1): 27-32, 1991.
82. Konecny G, Pauletti G et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. *J Natl Cancer Inst* 95 (2): 142-153, 2003.
83. Kraus MH, Issing W et al. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. *Proc Natl Acad Sci U S A* 86 (23): 9193-9197, 1989.
84. Kurebayashi J, Okubo S et al. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. *Breast Cancer* 11 (1): 38-41, 2004.
85. Kuukasjarvi T, Karhu R et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. *Cancer Res* 57 (8): 1597-1604, 1997.
86. Kuukasjarvi T, Kononen J et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. *J Clin Oncol* 14 (9): 2584-2589, 1996.
87. Lane HA, Beuvink I et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. *Mol Cell Biol* 20 (9): 3210-3223, 2000.
88. Lane HA, Motoyama AB et al. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. *Ann Oncol* 12 Suppl 1: S21-S22, 2001.
89. Lawson JS, Field AS et al. Low oestrogen receptor  $\alpha$  expression in normal breast tissue underlies low breast cancer incidence in Japan. *Lancet* 354 (9192): 1787-1788, 1999.
90. Leal CB, Schmitt FC et al. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. *Cancer* 75 (8): 2123-2131, 1995.

91. Lebeau A, Deimling D et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. *J Clin Oncol* 19 (2): 354-363, 2001.
92. Lemoine NR, Barnes DM et al. Expression of the ERBB3 gene product in breast cancer. *Br J Cancer* 66 (6): 1116-1121, 1992.
93. Levkowitz G, Klapper LN et al. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. *Oncogene* 12 (5): 1117-1125, 1996.
94. Lewis GD, Figari I et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. *Cancer Immunol Immunother* 37 (4): 255-263, 1993.
95. Lewis S, Locker A et al. Expression of epidermal growth factor receptor in breast carcinoma. *J Clin Pathol* 43 (5): 385-389, 1990.
96. Leygue E, Dotzlaw H et al. Altered estrogen receptor  $\alpha$  and  $\beta$  messenger RNA expression during human breast tumorigenesis. *Cancer Res* 58 (15): 3197-3201, 1998.
97. Leygue E, Hall RE et al. Oestrogen receptor- $\alpha$  variant mRNA expression in primary human breast tumours and matched lymph node metastases. *Br J Cancer* 79 (5-6): 978-983, 1999.
98. Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. *Biomed Pharmacother* 57 (10): 447-451, 2003.
99. Livingston RB, Esteva FJ. Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug? *Oncologist* 6 (4): 315-316, 2001.
100. Lodge AJ, Anderson JJ et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. *J Clin Pathol* 56 (4): 300-304, 2003.
101. Longy M, Duboue B et al. Method for the purification of tissue DNA suitable for PCR after fixation with Bouin's fluid. Uses and limitations in microsatellite typing. *Diagn Mol Pathol* 6 (3): 167-173, 1997.
102. Macias A, Azavedo E et al. Receptors for epidermal growth factor in human mammary carcinomas and their metastases. *Anticancer Res* 6 (4): 849-851, 1986.
103. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. *Ann Clin Lab Sci* 30 (3): 259-265, 2000.
104. Mass R, Sanders C, Kasian C. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in Herceptin(R) pivotal trials. *Proc Am Soc Clin Oncol* 19 (75a): 2000.
105. McKenzie SJ, Marks PJ et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. *Oncogene* 4 (5): 543-548, 1989.

106. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. *Oncogene* 19 (56): 6550-6565, 2000.
107. Molina MA, Codony-Servat J et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. *Cancer Res* 61 (12): 4744-4749, 2001.
108. Moreno A, Lloveras B et al. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. *Mod Pathol* 10 (11): 1088-1092, 1997.
109. Naidu R, Yadav M et al. Expression of c-erbB3 protein in primary breast carcinomas. *Br J Cancer* 78 (10): 1385-1390, 1998.
110. Nass SJ, Dickson RB. Defining a role for c-Myc in breast tumorigenesis. *Breast Cancer Res Treat* 44 (1): 1-22, 1997.
111. Newby JC, Johnston SR et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. *Clin Cancer Res* 3 (9): 1643-1651, 1997.
112. Nicholson RI, Hucheson IR et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. *Endocr Relat Cancer* 8 (3): 175-182, 2001.
113. Niehans GA, Singleton TP et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. *J Natl Cancer Inst* 85 (15): 1230-1235, 1993.
114. Padhy LC, Shih C et al. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. *Cell* 28 (4): 865-871, 1982.
115. Paget S. The distribution of secondary growths in cancer of the breast. 1889. *Cancer Metastasis Rev* 8 (2): 98-101, 1989.
116. Pallis L, Wilking N et al. Receptors for estrogen and progesterone in breast carcinoma in situ. *Anticancer Res* 12 (6B): 2113-2115, 1992.
117. Pardue ML, Gall JG. Molecular hybridization of radioactive DNA to the DNA of cytological preparations. *Proc Natl Acad Sci U S A* 64 (2): 600-604, 1969.
118. Pauletti G, Dandekar S et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. *J Clin Oncol* 18 (21): 3651-3664, 2000.
119. Pauletti G, Godolphin W et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. *Oncogene* 13 (1): 63-72, 1996.
120. Pawlowski V, Revillion F et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. *Clin Cancer Res* 6 (11): 4217-4225, 2000.



121. Pedersen MW, Meltorn M et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. *Ann Oncol* 12 (6): 745-760, 2001.
122. Penault-Llorca F, Adelaide J et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. *J Pathol* 173 (1): 65-75, 1994.
123. Plowman GD, Culouscou JM et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. *Proc Natl Acad Sci U S A* 90 (5): 1746-1750, 1993.
124. Plowman GD, Whitney GS et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. *Proc Natl Acad Sci U S A* 87 (13): 4905-4909, 1990.
125. Polosa R, Prosperini G et al. Expression of c-erbB receptors and ligands in human bronchial mucosa. *Am J Respir Cell Mol Biol* 20 (5): 914-923, 1999.
126. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. *Oncogene* 5 (7): 953-962, 1990.
127. Press MF, Hung G et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. *Cancer Res* 54 (10): 2771-2777, 1994.
128. Quinn CM, Ostrowski JL et al. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. *Histopathology* 25 (3): 247-252, 1994.
129. Rajkumar T, Gooden CS et al. Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. *J Pathol* 170 (3): 271-278, 1993.
130. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers – a review. *Gene* 159 (1): 19-27, 1995.
131. Ravdin PM, Green S et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. *J Clin Oncol* 10 (8): 1284-1291, 1992.
132. Rennstam K, Baldetorp B et al. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. *Cancer Res* 61 (3): 1214-1219, 2001.
133. Ricketts D, Turnbull L et al. Estrogen and progesterone receptors in the normal female breast. *Cancer Res* 51 (7): 1817-1822, 1991.
134. Rios MA, Macias A et al. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. *Anticancer Res* 8 (1): 173-176, 1988.

135. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. *Br J Cancer* 73 (1): 5-12, 1996.
136. Roger P, Sahla ME et al. Decreased expression of estrogen receptor  $\beta$  protein in proliferative preinvasive mammary tumors. *Cancer Res* 61 (6): 2537-2541, 2001.
137. Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. *Oncologist* 3 (4): 237-252, 1998.
138. Rossouw JE, Anderson GL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. *JAMA* 288 (3): 321-333, 2002.
139. Rubin I, Yarden Y. The basic biology of HER2. *Ann Oncol* 12 Suppl 1: S3-S8, 2001.
140. Sainsbury JR, Malcolm AJ et al. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. *J Clin Pathol* 38 (11): 1225-1228, 1985.
141. Salomon DS, Brandt R et al. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol* 19 (3): 183-232, 1995.
142. Sartor CI, Zhou H et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. *Mol Cell Biol* 21 (13): 4265-4275, 2001.
143. Sawyer C, Hiles I et al. Two erbB-4 transcripts are expressed in normal breast and in most breast cancers. *Oncogene* 17 (7): 919-924, 1998.
144. Seidman AD, Fornier MN et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. *J Clin Oncol* 19 (10): 2587-2595, 2001.
145. Shimizu C, Fukutomi T et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. *J Surg Oncol* 73 (1): 17-20, 2000.
146. Shoker BS, Jarvis C et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. *Am J Pathol* 155 (6): 1811-1815, 1999.
147. Slamon D. Herceptin: increasing survival in metastatic breast cancer. *Eur J Oncol Nurs* 4 (Sa): 24-29, 2000.
148. Slamon DJ, Clark GM et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 235 (4785): 177-182, 1987.
149. Slamon DJ, Godolphin W et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 244 (4905): 707-712, 1989.
150. Slamon DJ, Leyland-Jones B et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 344 (11): 783-792, 2001.

151. Sliwkowski MX, Lofgren JA et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). *Semin Oncol* 26 (4 Suppl 12): 60-70, 1999.
152. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. *Biol Reprod* 58 (3): 627-632, 1998.
153. Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor  $\beta$  in breast cancer. *Br J Surg* 87 (4): 405-409, 2000.
154. Spyrtos F, Ferrero-Pous M et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. *Cancer* 94 (8): 2151-2159, 2002.
155. Srinivasan R, Benton E et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1  $\alpha$ , neuregulin-1  $\beta$ , and betacellulin, in normal endometrium and endometrial cancer. *Clin Cancer Res* 5 (10): 2877-2883, 1999.
156. Srinivasan R, Gillett CE et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. *Cancer Res* 60 (6): 1483-1487, 2000.
157. Srinivasan R, Poulson R et al. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. *J Pathol* 185 (3): 236-245, 1998.
158. Stabenow R, Eisinger B. Brustkrebs. Epidemiologische Daten zum weiblichen Brustkrebs aus dem Gemeinsamen Krebsregister der Länder Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Schriftenreihe des GKR 1: 2001.
159. Stal O, Sullivan S et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. *Eur J Cancer* 31A (13-14): 2185-2190, 1995.
160. Stancovski I, Hurwitz E et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. *Proc Natl Acad Sci U S A* 88 (19): 8691-8695, 1991.
161. Stoica A, Saceda M et al. Regulation of estrogen receptor- $\alpha$  gene expression by epidermal growth factor. *J Endocrinol* 165 (2): 371-378, 2000.
162. Suo Z, Berner HS et al. Estrogen receptor- $\alpha$  and C-ERBB-4 expression in breast carcinomas. *Virchows Arch* 439 (1): 62-69, 2001.
163. Suo Z, Emilsen E et al. Type 1 protein tyrosine kinases in benign and malignant breast lesions. *Histopathology* 33 (6): 514-521, 1998.
164. Suo Z, Risberg B et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. *J Pathol* 196 (1): 17-25, 2002.
165. Tang CK, Concepcion XZ et al. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. *Cancer Res* 59 (20): 5315-5322, 1999.

166. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase II $\alpha$  in primary and metastatic breast cancer. *Cancer Res* 61 (14): 5345-5348, 2001.
167. Taylor JM, Mitchell WM, Cohen S. Characterization of the binding protein for epidermal growth factor. *J Biol Chem* 249 (7): 2188-2194, 1974.
168. Taylor JM, Mitchell WM, Cohen S. Characterization of the high molecular weight form of epidermal growth factor. *J Biol Chem* 249 (10): 3198-3203, 1974.
169. Tovey SM, Witton CJ et al. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. *Breast Cancer Res* 6 (3): R246-R251, 2004.
170. Travis A, Pinder SE et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. *Br J Cancer* 74 (2): 229-233, 1996.
171. Tsuda H, Hirohashi S et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. *Cancer Res* 49 (11): 3104-3108, 1989.
172. Tsuda H, Iwaya K et al. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. *Jpn J Cancer Res* 84 (4): 394-401, 1993.
173. Tsutsui S, Kataoka A et al. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. *Clin Cancer Res* 8 (11): 3454-3460, 2002.
174. Tzahar E, Waterman H et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. *Mol Cell Biol* 16 (10): 5276-5287, 1996.
175. Ullrich A, Coussens L et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309 (5967): 418-425, 1984.
176. Vladusic EA, Hornby AE et al. Expression of estrogen receptor  $\beta$  messenger RNA variant in breast cancer. *Cancer Res* 58 (2): 210-214, 1998.
177. Vogel CL, Cobleigh MA et al. First-line Herceptin monotherapy in metastatic breast cancer. *Oncology* 61 Suppl 2: 37-42, 2001.
178. Vogel CL, Cobleigh MA et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. *J Clin Oncol* 20 (3): 719-726, 2002.
179. Vogt U, Bielawski K et al. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. *Gene* 223 (1-2): 375-380, 1998.
180. von Minckwitz G, Brunnert K et al. Evidenz-basierte Empfehlungen zur Behandlung von lokoregionär und fernmetastasierten Mammakarzinomen. *Zentralbl Gynakol* 124 (5): 293-303, 2002.

181. Walker RA, Camplejohn RS. DNA flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors. *J Pathol* 150 (1): 37-42, 1986.
182. Witton CJ, Reeves JR et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. *J Pathol* 200 (3): 290-297, 2003.
183. Wright C, Nicholson S et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. *Br J Cancer* 65 (1): 118-121, 1992.
184. Yakes FM, Chinratanalab W et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. *Cancer Res* 62 (14): 4132-4141, 2002.
185. Yang XD, Jia XC et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. *Crit Rev Oncol Hematol* 38 (1): 17-23, 2001.
186. Yang XD, Jia XC et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. *Cancer Res* 59 (6): 1236-1243, 1999.
187. Yarden Y. Biology of HER2 and its importance in breast cancer. *Oncology* 61 Suppl 2: 1-13, 2001.
188. Yokota J, Yamamoto T et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. *Lancet* 1 (8484): 765-767, 1986.
189. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. *Bioessays* 22 (7): 673-680, 2000.
190. Zhou W, Carpenter G. ErbB-4: a receptor tyrosine kinase. *Inflamm Res* 51 (2): 91-101, 2002.